抄録
Aim: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). Patiets and Methods: The treatment schedule included cisplatin at 40 mg/m2 and vinorelbine at 25 mg/m2 administered intravenously on days 1 and 8, every three weeks for four cycles. Results: This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77%) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76%) and anemia (12%). The average total doses of cisplatin and vinorelbine were 285 mg/m2 and 177 mg/m2, respectively. Conclusion: The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 927-932 |
| ページ数 | 6 |
| ジャーナル | Anticancer research |
| 巻 | 34 |
| 発行部数 | 2 |
| 出版物ステータス | 出版済み - 2 1 2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
これを引用
Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer. / Hirai, Fumihiko; Seto, Takashi; Shimokawa, Mototsugu; Inamasu, Eiko; Toyozawa, Ryo; Toyokawa, Gouji; Yoshida, Tsukihisa; Shiraishi, Yoshimasa; Takenaka, Tomoyoshi; Yamaguchi, Masafumi; Takenoyama, Mitsuhiro; Ichinose, Yukito.
：: Anticancer research, 巻 34, 番号 2, 01.02.2014, p. 927-932.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer
AU - Hirai, Fumihiko
AU - Seto, Takashi
AU - Shimokawa, Mototsugu
AU - Inamasu, Eiko
AU - Toyozawa, Ryo
AU - Toyokawa, Gouji
AU - Yoshida, Tsukihisa
AU - Shiraishi, Yoshimasa
AU - Takenaka, Tomoyoshi
AU - Yamaguchi, Masafumi
AU - Takenoyama, Mitsuhiro
AU - Ichinose, Yukito
PY - 2014/2/1
Y1 - 2014/2/1
N2 - Aim: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). Patiets and Methods: The treatment schedule included cisplatin at 40 mg/m2 and vinorelbine at 25 mg/m2 administered intravenously on days 1 and 8, every three weeks for four cycles. Results: This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77%) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76%) and anemia (12%). The average total doses of cisplatin and vinorelbine were 285 mg/m2 and 177 mg/m2, respectively. Conclusion: The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.
AB - Aim: The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC). Patiets and Methods: The treatment schedule included cisplatin at 40 mg/m2 and vinorelbine at 25 mg/m2 administered intravenously on days 1 and 8, every three weeks for four cycles. Results: This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77%) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76%) and anemia (12%). The average total doses of cisplatin and vinorelbine were 285 mg/m2 and 177 mg/m2, respectively. Conclusion: The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=84897036148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897036148&partnerID=8YFLogxK
M3 - Article
C2 - 24511034
AN - SCOPUS:84897036148
VL - 34
SP - 927
EP - 932
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 2
ER -